logo-loader
viewSilence Therapeutics PLC

Silence Therapeutics - Additional Listing

RNS Number : 5883O
Silence Therapeutics PLC
01 June 2020
 

 

Additional listing

June 1, 2020

 

LONDON, Silence Therapeutics, PLC (LON: SLN) ("Silence" or "the Company") a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that it has today issued and allotted 30,000 new ordinary shares of 5p each ("New Ordinary Shares") following the exercise of share options under the Employee Share Option Scheme.

 

Application will be made to the London Stock Exchange for the New Ordinary Shares to be admitted to trading on AIM. Admission is expected to be effective on June 5, 2020. The New Ordinary Shares shall rank pari passu with the existing ordinary shares in the Company.

 

The total number of ordinary shares of 5p each in issue, following admission of the New Ordinary Shares, will be 82,826,259. The Company holds no shares in TreasuryThis figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in the Company under the FCA's Disclosure Guidance and Transparency Rules. 

 

 

Enquiries:

 

Silence Therapeutics plc

Iain Ross, Executive Chairman

Dr Rob Quinn, Chief Financial Officer

 

 

Tel:  +44 (0)20 3457 6900

  Investec Bank plc (Nominated Adviser and Broker)

Daniel Adams/Gary Clarence

 

  Tel:  +44 (0) 20 7597 5970

European IR

Consilium Strategic Communications

Mary-Jane Elliott/Chris Welsh/Angela Gray

[email protected]

 

Tel: +44 (0) 20 3709 5700

US IR

Westwicke Partners

Peter Vozzo

[email protected]

 

Tel: +1 (443) 213-0505

 

About Silence Therapeutics plc

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: https://www.silence-therapeutics.com/

 


This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.
 
END
 
 
ALSUPUMGQUPUGAG

Quick facts: Silence Therapeutics PLC

Price: 424

Market: AIM
Market Cap: £3.4 m
Follow

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Silence Therapeutics - Proactive One2One Virtual Event

Rob Quinn, from Silence Therapeutics (LON:SLN) pitches the company to investors at the Proactive One2One Virtual Event. Silence develops a new generation of medicines by harnessing the body’s natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can...

4 days, 10 hours ago